# FDA committee met on seven peptide-related groups of bulk drug substances

> FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.

- Evidence object: `story:fda-pcac-peptide-review-meeting:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-24
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-pcac-peptide-review-meeting/
- JSON record: https://peptidescanner.com/evidence/v1/objects/fda-pcac-peptide-review-meeting-v1.json
- Content SHA-256: `65097e7b6e0a9f128007ed9a4a1fb1b9a974c63e39ed02f4c43e1c5741807d3d`

## Claims and source pins

### Headline

FDA committee met on seven peptide-related groups of bulk drug substances ([`fda-pcac-peptide-meeting-2026`](#source-fda-pcac-peptide-meeting-2026))

### Summary

FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups. ([`fda-pcac-peptide-meeting-2026`](#source-fda-pcac-peptide-meeting-2026))

### Paragraph 1

FDA's meeting page groups the discussed bulk drug substances under BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500 and lists free-base and acetate forms for each of those seven peptide-related groups. ([`fda-pcac-peptide-meeting-2026`](#source-fda-pcac-peptide-meeting-2026))

### Paragraph 2

FDA's briefing documents say advisory-committee recommendations are nonbinding and that FDA will make final determinations only after completing the committee process and relevant reviews. This update reports the meeting, not a final FDA decision on any substance. ([`fda-bpc-157-briefing`](#source-fda-bpc-157-briefing), [`fda-emideltide-briefing`](#source-fda-emideltide-briefing), [`fda-epitalon-briefing`](#source-fda-epitalon-briefing), [`fda-kpv-briefing`](#source-fda-kpv-briefing), [`fda-mots-c-briefing`](#source-fda-mots-c-briefing), [`fda-semax-briefing`](#source-fda-semax-briefing), [`fda-tb-500-briefing`](#source-fda-tb-500-briefing))

## Sources

<a id="source-fda-pcac-peptide-meeting-2026"></a>
- **July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) (`fda-pcac-peptide-meeting-2026`)
<a id="source-fda-bpc-157-briefing"></a>
- **FDA briefing document for BPC-157-related bulk drug substances** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193343/download) (`fda-bpc-157-briefing`)
<a id="source-fda-emideltide-briefing"></a>
- **FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193344/download) (`fda-emideltide-briefing`)
<a id="source-fda-epitalon-briefing"></a>
- **FDA briefing document for epitalon** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193345/download) (`fda-epitalon-briefing`)
<a id="source-fda-kpv-briefing"></a>
- **FDA briefing document for KPV** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193346/download) (`fda-kpv-briefing`)
<a id="source-fda-mots-c-briefing"></a>
- **FDA briefing document for MOTS-c** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193347/download) (`fda-mots-c-briefing`)
<a id="source-fda-semax-briefing"></a>
- **FDA briefing document for Semax** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193348/download) (`fda-semax-briefing`)
<a id="source-fda-tb-500-briefing"></a>
- **FDA briefing document for TB-500** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/media/193349/download) (`fda-tb-500-briefing`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "FDA committee met on seven peptide-related groups of bulk drug substances." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/objects/fda-pcac-peptide-review-meeting-v1.json SHA-256: 65097e7b6e0a9f128007ed9a4a1fb1b9a974c63e39ed02f4c43e1c5741807d3d.